Fennec Pharmaceuticals (FENC) Free Cash Flow (2010 - 2025)

Fennec Pharmaceuticals (FENC) has 16 years of Free Cash Flow data on file, last reported at -$6.0 million in Q4 2025.

• Quarterly Free Cash Flow fell 304.48% year-over-year to -$6.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$12.5 million (down 149.42% YoY) and the FY2025 annual result came in at -$15.3 million, down 156.58% from the prior year.
• Free Cash Flow slipped to -$6.0 million in Q4 2025, from $1.5 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of $37.3 million in Q1 2024 to a low of -$8.4 million in Q2 2024.
• A 5-year average of -$1.8 million and a median of -$3.6 million in 2021 frame the typical range for Free Cash Flow.
• Annual changes were most pronounced in 2024 — Free Cash Flow surged 768.94% — and 2025, when it tumbled 304.48%.
• Tracing FENC's Free Cash Flow over 5 years: stood at -$3.2 million in 2021, then sank by 109.61% to -$6.8 million in 2022, then rose by 28.55% to -$4.9 million in 2023, then surged by 69.67% to -$1.5 million in 2024, then plunged by 304.48% to -$6.0 million in 2025.
• The last three Free Cash Flow figures came in at -$6.0 million (Q4 2025), $1.5 million (Q3 2025), and -$3.7 million (Q2 2025), per Business Quant data.